SCHEMBL2995695

SCHEMBL2995695

Oc1c2cc(Br)cc1Cc1cc(Br)cc(c1O)Cc1cc(Br)cc(c1O)Cc1cc(Br)cc(c1O)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.48
TSHR P16473 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
ING2 Q9H160 1/20 0.46
DUSP5 Q16690 1/20 0.43
DUSP6 Q16828 1/20 0.43
GABRA1 P14867 2/20 0.42
GABRB1 P18505 2/20 0.42
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42
PTPRB P23467 1/20 0.41
CD69 Q07108 1/20 0.36
AKR1C4 P17516 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
ERN1 O75460 1/20 0.34
PTPN2 P17706 1/20 0.33
PTPN1 P18031 1/20 0.33
PTPN4 P29074 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2992735 1.00 CYP3A4 (0.48) CYP3A4TSHRTDP1ING2DUSP5
SCHEMBL18538307 0.88 SLC6A2 (0.40) CYP3A4TSHRTDP1ING2DUSP5
SCHEMBL18538303 0.74 ING2 (0.68) ING2DUSP5DUSP6PTPRBCA1
SCHEMBL29634901 0.71 ING2 (0.46) CYP3A4ING2DUSP5DUSP6PTPRB
SCHEMBL13287042 0.71 SELL (0.48) CYP3A4ING2DUSP5DUSP6PTPRB
SCHEMBL979162 0.69 CYP19A1 (0.32)
SCHEMBL14848401 0.65 ING2 (0.46) TDP1ING2DUSP5DUSP6PTPRB
SCHEMBL13620669 0.65 GABRA1 (0.50) TDP1ING2DUSP5DUSP6GABRA1
SCHEMBL21260624 0.65 GABRA1 (0.46) ING2DUSP5DUSP6GABRA1GABRB1
SCHEMBL2471228 0.65 GABRA1 (0.50) TDP1ING2DUSP5DUSP6GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11027257-B2 Polycalixarene materials, methods of making same, and uses thereof NEW YORK UNIVERSITY IN ABU DHABI CORPORATION (AE) 2021-06-08 US claimed
US-20190015814-A1 POLYCALIXARENE MATERIALS, METHODS OF MAKING SAME, AND USES THEREOF NEW YORK UNIVERSITY IN ABU DHABI CORPORATION (AE) 2019-01-17 US claimed
US-11027257-B2 Polycalixarene materials, methods of making same, and uses thereof NEW YORK UNIVERSITY IN ABU DHABI CORPORATION (AE) 2021-06-08 US disclosed
US-20190015814-A1 POLYCALIXARENE MATERIALS, METHODS OF MAKING SAME, AND USES THEREOF NEW YORK UNIVERSITY IN ABU DHABI CORPORATION (AE) 2019-01-17 US disclosed
US-8252954-B2 Processes for the preparation of calixarene derivatives THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2012-08-28 US disclosed
US-20100185022-A1 PROCESSES FOR THE PREPARATION OF CALIXARENE DERIVATIVES THE UNIVERSITY OF WESTERN AUSTRALIA (AU) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100185022-A1 PROCESSES FOR THE PREPARATION OF CALIXARENE DERIVATIVES CALD1, CANX, CALU CYP3A4 1663/4885TSHR 4061/4885TDP1 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.